| Mr Jeffrey L Marlow, RPH | |
|
15909 Manchester Rd, Ellisville, MO 63011-2101 | |
| (636) 391-4064 | |
| (636) 527-7385 |
| Full Name | Mr Jeffrey L Marlow |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 15909 Manchester Rd, Ellisville, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174848766 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 051.033824 (Illinois) | Secondary |
| 183500000X | Pharmacist | 042019 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jeffrey L Marlow, RPH 15909 Manchester Rd, Ellisville, MO 63011-2101 Ph: (636) 391-4064 | Mr Jeffrey L Marlow, RPH 15909 Manchester Rd, Ellisville, MO 63011-2101 Ph: (636) 391-4064 |
News Archive
Researchers at the University of Warwick and UHCW have discovered how body clock genes could affect women's ability to have children.
Talecris Biotherapeutics, Inc. (TLCR) announced today that it has been granted orphan drug designation by the European Commission for the development of Plasmin (human) to treat acute peripheral arterial occlusion (aPAO). Talecris is currently investigating Plasmin in a phase II clinical trial designed to assess its ability to treat aPAO, a condition in which arterial blood flow to the extremities, usually the legs, is blocked by a clot.
Exposure in the womb to bisphenol A (BPA) - a chemical used to make plastic containers and other consumer goods - is associated with behavior and emotional problems in young girls, according to a study led by researchers at Harvard School of Public Health (HSPH), Cincinnati Children's Hospital and Medical Center, and Simon Fraser University in Vancouver, British Columbia.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.
› Verified 2 days ago
Mr. Musadiq Jeddy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 636-527-5074 | |
Madison Elisabeth Harper, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 309-202-3394 Fax: 636-527-6456 | |
Mrs. Cortney Renae Robinson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 | |
Linda Lui, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 | |
Dr. Richard Briggs, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 636-527-6074 | |
Hawa Awad, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 |